Pure Erythroid Leukemia Mimicking Ewing Sarcoma/Primitive Neuroectodermal Tumor in an Infant

Pediatric Blood & Cancer
Razvan LapadatGabriela Gheorghe

Abstract

Pure erythroid leukemia (PEL) is a rare type of acute myeloid leukemia (AML) with a very aggressive clinical course. Presentation as a myeloid/erythroid sarcoma is exceedingly rare. We describe an infantile PEL presenting as a multifocal myeloid sarcoma, clinically and pathologically mimicking Ewing sarcoma/PNET family of tumors. The patient died 8 weeks after the initial presentation due to widespread disease. Our case shows that PEL needs to be considered in the differential diagnosis of small round blue cell tumors in infancy. A meticulous workup including immunohistochemistry, flow cytometry, molecular, and cytogenetic studies was required to reach the diagnosis.

References

Jan 1, 1990·Oral Surgery, Oral Medicine, and Oral Pathology·R E WoodF Grotepass
Feb 1, 1988·Molecular and Cellular Biology·M F ClarkeE V Prochownik
Jul 20, 2007·Journal of Oral Science·Sérgio L P C LopesFernando Cendes
Sep 17, 2009·Internal Medicine·Junichi KitagawaHisataka Moriwaki
Nov 26, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Wei LiuSa A Wang
Dec 14, 2011·Human Pathology·Sa A Wang, Robert P Hasserjian
Dec 22, 2011·Internal Medicine·Yohei FunakoshiHironobu Minami
Jun 1, 2010·Journal of Toxicologic Pathology·Emi YamamotoNoriko Tsuchiya

❮ Previous
Next ❯

Citations

May 20, 2017·International Journal of Hematology·Akihiro TamuraYoshiyuki Kosaka
Jan 18, 2020·British Journal of Haematology·Benjamin TomlinsonErika M Moore
Nov 20, 2018·The Journal of Veterinary Medical Science·Fusae OgasawaraKoichi Kadota
Dec 15, 2020·American Journal of Clinical Pathology·Rebecca L KingHarneet Hara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Journal of Pediatric Hematology/oncology
Sree Rekha JinkalaArpita Bhaumik
Applied Immunohistochemistry & Molecular Morphology : AIMM
Rogério Cardoso da SilvaCarlos E Bacchi
© 2022 Meta ULC. All rights reserved